EpiCast Report: Uveitis - Epidemiology Forecast to 2026

EpiCast Report: Uveitis - Epidemiology Forecast to 2026

  • GlobalData
  • November 2017
  • Pharmaceutical
  • 43 pages

Report Description

EpiCast Report: Uveitis - Epidemiology Forecast to 2026


Uveitis is the inflammation of the uveal tract (iris, ciliary body, and choroid), but can also cause the inflammation of nearby tissues, such as the retina, the optic nerve, and the vitreous humor. Anatomically, uveitis is classified by the main site of inflammation as anterior, intermediate, posterior, and panuveitis. Anterior uveitis is the most common form, is localized to the anterior chamber of the eye, and includes iritis, iridocyclitis, and anterior cylitis. Uveitis can occur in an acute, recurrent, or chronic manner.

This analysis provides detailed, granular, and clinically-relevant segmentations of uveitis cases. This analysis is further strengthened by its adherence to the standard clinical guidelines provided by the IUSG and SUN. By using the same guidelines across the different markets, GlobalData epidemiologists were able to conduct meaningful comparisons and analyses of the forecast results.

In the 7MM, the diagnosed incident cases of uveitis will increase from 402,343 cases in 2016 to 420,627 cases in 2026, at an Annual Growth Rate (AGR) of 0.45% per year. GlobalData forecasts that all markets except Germany and Japan will see an increase in the diagnosed incident cases of uveitis during the forecast period. In 2016, there were 992,827 diagnosed prevalent cases of uveitis in the 7MM, which is expected to increase to 1,115,226 cases by 2026, at an AGR of 1.23%. Among the 7MM, the US had the highest number of diagnosed prevalent cases of uveitis in 2016 and 2026, at 361,513 cases and 414,835 cases, respectively.


- The Uveitis EpiCast Report provides an overview of the risk factors and global trends of uveitis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- It also includes a 10-year epidemiology forecast of the diagnosed incident and diagnosed prevalent cases of uveitis in these markets from 2016-2026. The diagnosed incident and prevalent cases are further segmented by sex and age (starting at age 0 years up to ages 80 years and older) and by anatomical site of inflammation (anterior, intermediate, posterior, and panuveitis). The diagnosed incident cases are also segmented by course of disease (acute, chronic, and recurrent).
- The uveitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Uveitis EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global uveitis market.
- Quantify patient populations in the global uveitis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for uveitis therapeutics in each of the markets covered.
- Understand magnitude of uveitis population by course of disease and anatomical site of inflammation.

Have query on this report?

Make an Enquiry
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Uveitis: Executive Summary 4

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.


get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074